Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cognitive research firms Network Neurometrics and Cogtest have joined forces to speed the development of effective treatments for disorders ranging from Alzheimer's disease and schizophrenia, to diabetes and heart disease.
Subscribe to our email newsletter
The two companies have announced a collaborative agreement whereby the clinical facilities, trial site networks, proprietary technologies and scientific expertise of each company would be made available to the other.
The clinical facilities of the two companies stretch across the US and Europe to China and India. The technologies include a broad range of state-of-the-art computerized cognitive tests and batteries, forming a library of tests for discovering drug effects and providing assessments optimized for specific compounds and patient groups.
The full spectrum of cognitive drug development services provided by the two companies includes trial design and planning clinical development programs; site selection, study implementation and supervision; and data management, statistical analysis and report writing.
Cogtest’s chief executive, Dr Tonmoy Sharma, said: “I am very excited by the potential of the shared knowledge and expertise in these two companies. Together NetMet and Cogtest will provide pharmaceutical and biotechnology companies with a turn-key solution for evaluating these new and exciting drugs for disorders affecting cognitive function, and bring them to those in need as quickly as possible.”